Biohaven Pharmaceutical Holding Company Ltd.
Stock Forecast, Prediction & Price Target
Biohaven Pharmaceutical Holding Company Ltd. (BHVN) stock Price Target by analysts
$60.6
Potential upside: 291.22%
Biohaven Pharmaceutical Holding Company Ltd. price prediction
What is Biohaven Pharmaceutical Holding Company Ltd. stock analysts` prediction?
Biohaven Pharmaceutical Holding Company Ltd. stock forecast: Based on 8 Wall Street analysts` predicted price targets for Biohaven Pharmaceutical Holding Company Ltd. in the last 3 months, the avarage price target is $60.6, with a high forecast of $NaN. The average price target represents a 291.22% change from the last price of $15.49.
Disclaimer: This is not investment advice. Don't use price targets as the only investment indicator. Always remember to do your own thorough research and due diligence before making an investment decision.
Biohaven Pharmaceutical Holding Company Ltd. stock Price Target by analysts
Full breakdown of analysts given Biohaven Pharmaceutical Holding Company Ltd. price targets
| Analyst name & company | Analyst win rate | Publish date | Price target | Price when posted | Source | Historical targets |
|---|---|---|---|---|---|---|
Leonid Timashev RBC Capital | 0% 0/3 | 9 months ago | $61 293.80% upside | $46.58 | StreetInsider | Previous targets (2) |
Jason Gerberry Bank of America Securities | 0% 0/2 | 11 months ago | $65 319.62% upside | $52.77 | StreetInsider | Previous targets (1) |
Leonid Timashev RBC Capital | 0% 0/3 | 11 months ago | $68 338.99% upside | $45.94 | StreetInsider | Previous targets (2) |
Jason Gerberry Bank of America Securities | 0% 0/2 | 11 months ago | $62 300.25% upside | $45.94 | StreetInsider | Previous targets (1) |
Douglas Tsao H.C. Wainwright | 0% 0/1 | 11 months ago | $59 280.89% upside | $45.94 | StreetInsider | Previous targets (0) |
Marc Goodman Leerink Partners | 0% 0/1 | 11 months ago | $60 287.34% upside | $44.22 | StreetInsider | Previous targets (0) |
Brian Skorney Robert W. Baird | 0% 0/2 | 11 months ago | $60 287.34% upside | $46.56 | StreetInsider | Previous targets (1) |
Thomas Shrader BTIG | 0% 0/1 | 11 months ago | $59 280.89% upside | $46.56 | StreetInsider | Previous targets (0) |
Amy Li Jefferies | 0% 0/1 | 12 months ago | $57 267.97% upside | $38.08 | TheFly | Previous targets (0) |
William Pickering Tudor Pickering | 0% 0/1 | 12 months ago | $55 255.06% upside | $38.17 | TheFly | Previous targets (0) |
Terence Flynn Morgan Stanley | 0% 0/1 | about 1 year ago | $58 274.43% upside | $37.81 | TheFly | Previous targets (0) |
Leonid Timashev RBC Capital | 0% 0/3 | over 1 year ago | $59 280.89% upside | $28.69 | StreetInsider | Previous targets (2) |
Brian Skorney Robert W. Baird | 0% 0/2 | over 1 year ago | $58 274.43% upside | $30.31 | TheFly | Previous targets (1) |
Unknown J.P. Morgan | N/A | over 2 years ago | $23 48.48% upside | $13.5 | Benzinga | N/A |
Unknown BTIG | N/A | over 2 years ago | $24 54.93% upside | $16.53 | Benzinga | N/A |
Paul Choi Goldman Sachs | 0% 0/1 | almost 4 years ago | $170 997.48% upside | $141.24 | StreetInsider | Previous targets (0) |
Ken Cacciatore Cowen & Co. | 0% 0/1 | almost 4 years ago | $165 965.20% upside | $142.72 | StreetInsider | Previous targets (0) |
Biohaven Pharmaceutical Holding Company Ltd. Financial Estimates
Biohaven Pharmaceutical Holding Company Ltd. Revenue Estimates
Biohaven Pharmaceutical Holding Company Ltd. EBITDA Estimates
Biohaven Pharmaceutical Holding Company Ltd. Earnings per Share Estimates
| Passed | Analyst forecast | ||||||
|---|---|---|---|---|---|---|---|
| Metric | 12/31/2021 | 12/31/2022 | 12/31/2023 | 12/31/2025 | 12/31/2026 | 12/31/2027 | 12/31/2028 |
Revenue
% change YoY
| $462.50M N/A | $0 -100% | $0 0% | Avg: $11.18M Low: $3.24M High: $16.90M avg. 0% | Avg: $124.66M Low: $102.64M High: $140.49M avg. 1014.13% | Avg: $457.64M Low: $376.80M High: $515.75M avg. 267.10% | Avg: $785.48M Low: $646.74M High: $885.22M avg. 71.63% |
Net Income
% change YoY
| $-213.79M N/A | $-570.27M -166.73% | $-408.16M 28.42% | Avg: $-663.90M Low: $-565.33M High: $-373.35M avg. -62.65% | Avg: $-639.80M Low: $-580.28M High: $-342.98M avg. 3.63% | Avg: $-315.13M Low: $-367.15M High: $-242.77M avg. 50.74% | Avg: $-162.62M Low: $-189.46M High: $-125.28M avg. 48.39% |
EBITDA
% change YoY
| $-217.50M N/A | $-566.54M -160.47% | $-429.13M 24.25% | Avg: $7.89M Low: $2.28M High: $11.93M avg. 101.84% | Avg: $88.00M Low: $72.46M High: $99.18M avg. 1014.13% | Avg: $323.07M Low: $266.00M High: $364.09M avg. 267.10% | Avg: $554.51M Low: $456.56M High: $624.91M avg. 71.63% |
EPS
% change YoY
| -$5.97 N/A | -$12.75 -113.56% | -$5.73 55.05% | Avg: -$6.82 Low: -$7.94 High: -$5.24 avg. -18.98% | Avg: -$5.9 Low: -$8.15 High: -$4.82 avg. 13.49% | Avg: -$4.43 Low: -$5.16 High: -$3.41 avg. 24.95% | Avg: -$2.28 Low: -$2.66 High: -$1.76 avg. 48.39% |
Operating Expenses
% change YoY
| $218.9M N/A | $567.93M 159.44% | $436.05M -23.22% | Avg: $9.13M Low: $2.64M High: $13.79M avg. -97.90% | Avg: $101.74M Low: $83.77M High: $114.66M avg. 1014.13% | Avg: $373.51M Low: $307.54M High: $420.94M avg. 267.10% | Avg: $641.09M Low: $527.85M High: $722.49M avg. 71.63% |
FAQ
What is Biohaven Pharmaceutical Holding Company Ltd. stock earnings growth forecast?
Wall Street analysts estimate the annual average earnings growth rate of 10.02% in 2025-2028.
We have gathered data from 8 analysts. Their low estimate is -565.33M, average is -663.90M and high is -373.35M.
What is Biohaven Pharmaceutical Holding Company Ltd. stock revenue growth forecast?
Wall Street analysts forecast annual average revenue growth of 338.21% in 2025-2028.
We have gathered data from 7 analysts. Their low revenue estimate is $3.24M, average is $11.18M and high is $16.90M.
What is Biohaven Pharmaceutical Holding Company Ltd. stock earnings per share growth forecast?
Wall Street analysts forecast annual average earnings growth of 16.96% in 2025-2028.
We have gathered data from 8 analysts. Their low earnings per share estimate is -$7.94, average is -$6.82 and high is $-5.24.
What is the best performing analyst?
In the last twelve months 8 analysts have been covering Biohaven Pharmaceutical Holding Company Ltd. stock. The most successful analyst is Leonid Timashev.